Author's response to reviews Title:Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report Authors:
نویسندگان
چکیده
Takuto Nosaka ([email protected]) Katsushi Hiramatsu ([email protected]) Tomoyuki Nemoto ([email protected]) Yasushi Saito ([email protected]) Yoshihiko Ozaki ([email protected]) Kazuto Takahashi ([email protected]) Tatsushi Naito ([email protected]) Kazuya Ofuji ([email protected]) Hidetaka Matsuda ([email protected]) Masahiro Ohtani ([email protected]) Hiroyuki Suto ([email protected]) Yoshiaki Imamura ([email protected]) Yasunari Nakamoto ([email protected])
منابع مشابه
Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report
BACKGROUND The spontaneous rupture of hepatic metastases is rare compared to that of primary hepatic tumors. In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation. CASE PRESENTATION A 44-year-old female had previously undergone surgery for res...
متن کاملAbstract: Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unre- sectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients
Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafe...
متن کاملConjunctival melanomas harbor BRAF and NRAS mutations--response.
In our recently published study (1), we describe genetic similarities between conjunctival and cutaneousmelanoma and propose that the treatment rationale for patients with metastasized conjunctival melanoma should be adapted to that for metastasized cutaneous melanoma. Weber and colleagues (2) responded to this, reporting that a BRAF V600E–mutant metastasized conjunctival melanoma patient treat...
متن کاملLong-lasting tumor response on short-time administration of vemurafenib—A case report
INTRODUCTION Vemurafenib has been approved since 2011 in the United States for the treatment of advanced BRAF V600emutated melanoma as first-line therapy. Although it significantly prolongs overall and progression-free survival, most patients relapse within 6 to 8 months owing to acquisition of drug resistance. New findings suggest that discontinuous dose administration of vemurafenib might pro...
متن کاملMetastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patient's therapeutical scheme. After com...
متن کامل